Patents by Inventor Anna Sall
Anna Sall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117074Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).Type: ApplicationFiled: November 13, 2023Publication date: April 11, 2024Inventors: PETER ELLMARK, KARIN HAGERBRAND, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
-
Patent number: 11873348Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).Type: GrantFiled: November 4, 2022Date of Patent: January 16, 2024Assignee: ALLIGATOR BIOSCIENCE ABInventors: Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
-
Publication number: 20230312754Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).Type: ApplicationFiled: November 4, 2022Publication date: October 5, 2023Inventors: Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
-
Publication number: 20230295325Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: ApplicationFiled: November 10, 2022Publication date: September 21, 2023Inventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
-
Patent number: 11725060Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: GrantFiled: July 20, 2018Date of Patent: August 15, 2023Assignees: Aptevo Reserch and Development LLC, Alligator Bioscience ABInventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Van Citters, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Patent number: 11535678Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: GrantFiled: November 21, 2017Date of Patent: December 27, 2022Assignee: ALLIGATOR BIOSCIENCE ABInventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
-
Publication number: 20220213213Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.Type: ApplicationFiled: September 23, 2021Publication date: July 7, 2022Inventors: Eva DAHLÉN, Peter ELLMARK, Christina FUREBRING, Per NORLÉN, Anna SÄLL, Laura von SCHANTZ, Niina VEITONMÄKI, Laura VARAS, Jessica PETERSSON, Sara FRITZELL
-
Patent number: 11312786Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: GrantFiled: February 21, 2019Date of Patent: April 26, 2022Assignees: Aptevo Research and Development LLC, Alligator Bioscience ABInventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Publication number: 20220073635Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.Type: ApplicationFiled: December 17, 2019Publication date: March 10, 2022Inventors: Anna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
-
Publication number: 20220064325Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of targeting a dendritic cell, and a second binding domain, designated B2, which is capable of targeting a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.Type: ApplicationFiled: December 17, 2019Publication date: March 3, 2022Inventors: Anna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
-
Publication number: 20220056148Abstract: The present invention provides bispecific antibodies of an antibody format, and which comprise one or more Fab fragments and an immunoglobulin molecule. The invention further provides compositions of said bispecific antibodies, as well as methods and uses of the same. The invention further provides a method of generating bispecific antibodies of the format.Type: ApplicationFiled: December 17, 2019Publication date: February 24, 2022Inventors: Anna Sall, Laura Von Schantz, Anneli Nilsson, Barnabas Nyesiga, Jessica Petersson, Mattias Levin
-
Publication number: 20200223933Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: ApplicationFiled: July 20, 2018Publication date: July 16, 2020Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Patent number: 10689454Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: GrantFiled: July 17, 2019Date of Patent: June 23, 2020Assignee: ALLIGATOR BIOSCIENCE ABInventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
-
Publication number: 20190382503Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: ApplicationFiled: February 21, 2019Publication date: December 19, 2019Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Publication number: 20190352414Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: ApplicationFiled: July 17, 2019Publication date: November 21, 2019Inventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
-
Publication number: 20190352411Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: ApplicationFiled: November 21, 2017Publication date: November 21, 2019Inventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
-
Publication number: 20190169308Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.Type: ApplicationFiled: April 24, 2017Publication date: June 6, 2019Inventors: Eva Dahlén, Peter Ellmark, Christina Furebring, Per Norlén, Anna Säll, Laura von Schantz, Niina Veitonmäki, Laura Varas, Jessica Petersson, Sara Fritzell
-
Patent number: 10239949Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: GrantFiled: July 20, 2018Date of Patent: March 26, 2019Assignees: Aptevo Research and Development, LLC, Alligator Bioscience ABInventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Publication number: 20190016816Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: ApplicationFiled: July 20, 2018Publication date: January 17, 2019Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas